Antiviral cytotoxic T lymphocytes (CTL) are specifically induced against viral antigens presented by MHC class I molecules on the surface of infected cells (1). The intracellularly synthesized antigens are processed and associated with class I antigens within cells in a yet poorly defined way before presentation on the cell surface (2). Induced effector CTL also recognize synthetic peptides bound by MHC class I molecules from without on the cell surface in absence of an apparent need for cell internal processing (3, 4).
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BRIEF DEFINITIVE REPORT Virus. The LCMVWE strain was originally obtained from Dr. F. Lehmann-Grube, Hamburg, FRG, and was grown in L929 fibroblast cells (12) . The vaccinia virus WR strain was grown in BSC-1 cells . Recombinant vaccinia virus expressing amino acids (aa) 1-202 of the LCMV nucleoprotein (vaccNP2) was constructed and grown as described (10) .
Synthetic Peptides. Peptides were synthesized manually by the solid-phase method (13, 14) on p-alkoxybenzyl alcohol resin (15) . Fluorenylmethyloxycarbonyl (Fmoc-) strategy was used throughout the synthesis (Fmoc-N-a and TU side chain protection) (14) . Peptides were cleaved from the resin by 55 % trifluoroacetate in dichloromethane, purified by reverse-phase HPLC, ion-exchanged, and lyophilized. The freeze-dried material was analyzed on an Aminoquant HP 1046A amino acid analyzer and by (+)FAB mass spectroscopy.
Monoclonal Antibodies . The mAbs YTS 169.4 (anti-CD8) and YTS 191 .1 (anti-CD4) (16) and low tox rabbit complement (Cedarlane Laboratories, Ontario, Canada) were used to deplete lymphocyte subpopulations in vitro.
Priming of Mice and Lymphocyte Cultures . BALB/c (H-2d) mice were primed subcutaneously at the base of the tail with 100 1~g free peptide in IFA three times with 1-wk intervals . 7 d after the last injection lymphocytes from draining lymphnodes were restimulated in vitro (3 x 106/well) with irradiated syngeneic spleen cells (6 x 106/well) in 24-well Costar plates in 10% FCS/Iscove's modified Dulbecco Medium for 6 d. Stimulator cells were sensitized in vitro with 100-200,ug peptide/ml for 3 h and washed before use. Alternatively, mice were injected once intravenously with 4 x 106 PFU recombinant vaccinia virus (vaccNP2) and 6 wk later lymphocytes from spleens were restimulated in vitro as described .
Cytotoxiciy Assay. In vitro restimulated lymphocytes from lymphnodes or spleens or primary LCMV immune bulk splenocytes from mice infected intravenously with 200 PFU LCMVWE 8 d previously were tested on appropriate target cells, B10 .D2 (H-2d) and DBA/l (H-29), as described in detail elsewhere (10) .
Results and Discussion
Major T Cell Epitope in H-2d Mice. The major T cell response in BALB/c (H-2d) mice is directed against the as 112-132 region of LCMV nucleoprotein ; the peptide as 118-132 is well recognized by CTL in association with Ld (10, 11) (Fig. 1 A) . The cytotoxic T cell response of H-2 d mice to LCMV resulted in lysis of target cells infected with LCMV or preincubated with peptide as 118-132, but not of target cells if preincubated with LCMV nucleoprotein peptide as 157-171 ( Fig. 1 B) . These two peptides were used in the following studies as relevant/positive (aa 118-132) and irrelevant/negative (aa 157-171) peptide antigens.
Induction In Vivo of LCMVand Peptide-specific CTL by a T Cell Epitope Peptide . The capacity of these peptides to induce a peptide-and virus-specific CTL response in vivo was evaluated in H-2 d mice by subcutaneous injection of unmodified free peptides emulsified in IFA. 7 d after the last injection the lymphocytes from the draining lymphnodes were isolated and restimulated in vitro with irradiated syngeneic spleen cells coated with the relevant or irrelevant peptide . Lymphocytes from mice primed with peptide as 118-132 and restimulated with this peptide in vitro generated a specific cytotoxic T cell response against LCMVinfected and peptide-coated target cells (Fig.  2 A) . The response was specific since neither peptide as 157-171-coated target cells nor vaccinia virus WR-infected target cells were recognized by peptide as 118-132-primed lymphocytes .
Restimulation of this same effector population was specific since peptide as 157-171-coated stimulator cells failed to induce a significant response (Fig. 2 B) .
When the peptide as 157-171 was used for in vivo priming and peptide as 118-132 for restimulation in vitro, no specific T cell response was generated neither against the irrelevant peptide nor the peptide as 118-132 (Fig. 2 C) . This result shows that the relevant peptide as 118-132 cannot readily induce a virus-specific effector population in vitro. Both priming and restimulation with the irrelevant peptide as 157-171 failed to induce a specific CTL response to any of the described target cells (Fig. 2 D) .
A comparable CTL response is triggered in mice by infection with a recombinant vaccinia virus expressing the relevant subregion as 1-202 of the nucleoprotein of LCMV (10) . This subunit vaccine expresses all the nucleoprotein sequences necessary for endogenous processing ofthe antigen (17) . T lymphocytes from mice primed with vaccNP2 (aa 1-202) express specific cytotoxic activity only when restimulated in vitro with the relevant peptide as 118-132 (Fig. 2 E) but not with peptide as 157-171 (Fig. 2 F) . The specific effector T cell population induced by peptide as 118-132 in IFA and those induced by recombinant vaccinia virus vaccNP2 and restimulated in vitro were comparably specific for LCMV infected target cells and for target cells coated with peptide as 118-132 (Fig . 2 A, E) .
In Vivo Peptide Primed Cytotoxic Activity Is Mediated by CD8+ and MHC Class I-restricted T Cells. The following experiments were performed to exclude that free peptides might induce CD4+ effector lymphocytes and to confirm that effector cells were classical CD8i CTLs. Effector T cells induced by peptide as 118-132 in vivo (Fig. 2  A) were susceptible to treatment with anti-CD8 plus complement, whereas treatment with anti-CD4 had no effect (Fig. 3 A) .
In vivo peptide-primed cytotoxic T cells of BALE/c (H-2d) origin were tested on syngeneic (H-2 d , B10.D2) and allogeneic (H-2v, DBA/1) target cells infected with LCMV Both target cells do not express class II MHC antigens . There is a clear restriction specificity for H-2d target cells ( Fig. 3 B) ; this specificity control is particularly convincing since the same T cell epitope defined by peptide as 118-132 of LCMV nucleoprotein is recognized on H-2 Ld (10, 18) and H-2 L9 (Schulz, M., P Aichele, R . M. Zinkernagel, and H. Hengartner, manuscript in preparation) . BRIEF DEFINITIVE REPORT The present results show that unmodified viral peptides mixed with a mild adjuvant (not containing BCG) are able to induce MHC-dependent, virus-specific cytotoxic T cells in vivo. Together with the recent demonstration that peptides covalently linked to a lipid component (9) can readily induce a CTL response, the present evidence suggests that cocktails ofviral peptides may be used as antiviral T cell vaccines . 
Summary
Induction in vivo of antiviral cytotoxic T cell response was achieved in a MHC class I-dependent fashion by immunizing mice three times with a free unmodified 15-mer peptide derived from the nucleoprotein oflymphocytic choriomeningitis virus in IFA . The effector T cells are CD8+ , restricted to the class I Ld allele of the analyzed mouse strain, and are specific both at the level of secondary restimulation in vitro and at the effector T cell level. These results suggest that cocktails ofviral peptides may be used as antiviral T cell vaccines .
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